Search Thermo Fisher Scientific
The latest solutions and innovations for immuno-oncology research
Form submitted successfully. Thank you!
You may download the posters below.
Elevated TCRB repertoire convergence and clonal expansion in the NSCLC tumor microenvironment of responders to anti-PD-1 monotherapy
Automated rarefaction analysis for precision human and mouse B and T cell receptor repertoire profiling from peripheral blood and FFPE-preserved specimens
Evaluation of a tumor-only pan-cancer targeted semi-conductor based next-generation sequencing (NGS) test for microsatellite instability in FFPE samples
Development of a pan-cancer NGS assay for detection of tumor mutational burden and targeted biomarkers from FFPE samples
Please visit other areas of our site to learn how our next-generation sequencing solutions can take your immuno-oncology research to the next level.
Immuno-oncology therapies are considered to be promising anti-cancer treatments, generating excitement and hope among researchers, clinicians and patients. The Ion Torrent portfolio of immuno-oncology assays uses the sensitivity of next-generation sequencing (NGS) to help researchers decipher the cancer-immunity cycle within precious samples.
Studies aimed at leveraging an individual’s own immune system as a potential strategy toward the advancement of precision oncology has been a shared goal of scientists for many years. However, the complexities of tumor–immune interactions warrant a multidimensional approach to facilitate well-designed translational research studies and interpretation of results. Genomic analysis solutions based on next-generation sequencing (NGS) can be powerful tools to help gain significant insights in translational and clinical research.
For Research Use Only. Not for use in diagnostic procedures.